<DOC>
	<DOCNO>NCT02414828</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled dose-escalation study adult recently treat pulmonary TB . The dose AERAS-402 increase successive dose group . Enrollment dose group sequential . Enrollees stratify base time start TB treatment . The `` on-TB-treatment '' stratum start TB treatment 1 4 month ( 30 120 calendar day ) prior Study Day 0 . The `` post-TB-treatment '' stratum start TB treatment least 12 month ( 360 calendar day ) prior Study Day 0 . Subjects randomize receive placebo AERAS-402 vaccine . In Dose Groups 1 2 , subject randomize receive single injection AERAS-402 placebo . Dose Group 3 subject randomize receive two injection study day 0 study day 42 AERAS-402 placebo .</brief_summary>
	<brief_title>A Study Evaluate Safety AERAS-402 Adults Recently Treated Pulmonary TB</brief_title>
	<detailed_description>A total 72 subject randomize study . Subjects stratify , base time start TB treatment , 'on-TB-treatment ' stratum ( TB treatment start 1 4 month prior Study Day 0 ) 'post-TB-treatment ' stratum ( TB treatment start least 12 month Study Day 0 ) . In on-TB-treatment stratum , 36 subject randomize receive AERAS-402 placebo follow : 1 2 dos placebo ( N=5 ) ; 1 dose AERAS-402 3 x 10^8 vp ( N=5 ) 3 x 10^9 vp ( N=10 ) , 2 dos AERAS-402 3 x 10^10 vp ( N=16 ) . In post-TB-treatment stratum , 36 subject randomize receive AERAS-402 placebo follow : 1 2 dos placebo ( N=6 ) ; 1 dose AERAS-402 3 x 10^8 vp ( N=5 ) 3 x 109 vp ( N=10 ) , 2 dos AERAS-402 3 x 10^10 vp ( N=15 ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Is male female . 2 . Is age 18 45 year Study Day 0 . 3 . Has complete write informed consent process . 4 . Has history pulmonary tuberculosis diagnose either sputum smear positive acidfast bacillus ( AFB ) sputum culture positive Mtb . 5 . Has initiate effective chemotherapy tuberculosis one month ( 30 day ) four month ( 120 day ) Study Day 0 , improvement clinical sign and/or symptom disease , OR : initiate effective chemotherapy tuberculosis least 12 month ( 360 day ) Study Day 0 , consider cure . 6 . For subject currently receive chemotherapy tuberculosis must fully compliant previously prescribe tuberculosis therapy agree complete currently prescribe tuberculosis therapy . 7 . Agrees avoid elective surgery full duration study . 8 . For female subject : agree avoid pregnancy full duration study . 9 . Agrees stay contact study site full duration study , provide update contact information necessary , current plan move study area duration study . 10 . Has complete simultaneous enrollment Aeras Vaccine Development Registry Protocol . 1 . Fever ≥37.5°C . 2 . Evidence new acute illness may compromise safety subject study . 3 . Evidence significant active infection tuberculosis . 4 . Evidence central nervous system tuberculosis pleural tuberculosis . 5 . Previous medical history may compromise safety subject study , include limited : severe impairment pulmonary function tuberculosis infection pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy infantile spasm . 6 . Evidence systemic disease acute chronic illness may interfere evaluation safety vaccine . 7 . History laboratory evidence past , present future possible immunodeficiency state , include limited laboratory indication HIV1 infection . 8 . History allergic disease reaction likely exacerbate component study vaccine . 9 . Received investigational drug therapy vaccine within 182 day first dose study vaccine protocol . 10 . Received adenovirusbased vaccine previously . 11 . For female subject : Currently pregnant , lactating/nursing , positive serum urine βhCG 12 . Severe anemia , define hemoglobin le 10 g/dL hematocrit le 30 percent . 13 . Urine toxicology screen positive opiate , cocaine , amphetamine . 14 . Anal intercourse another man least one time ( without condom ) . 15 . Exchange good , money , service drug sex . 16 . Use intravenous drug . 17 . Sexual intercourse genital contact within last 12 month know HIV positive individual . 18 . Vaginal intercourse within last 12 month without use condom know user intravenous drug . 19 . Oral genital contact within last 12 month know user intravenous drug . 20 . Vaginal intercourse within last 12 month without use condom individual know one sex partner . 21 . Oral genital contact within last 12 month individual know one sex partner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>